Novartis AG
A TRIPLE PHARMACEUTICAL COMBINATION COMPRISING DABRAFENIB, TRAMETINIB AND AN ERK INHIBITOR

Abstract:

The present invention relates to a pharmaceutical combination comprising dabrafenib, trametinib and an Erk-inhibitor; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in which MAPK pathway inhibition is beneficial, for example, in the treatment of cancers.